Manganese ion doped ferrite nanoparticles, preparation method and application thereof
By doping Mn2+ ions instead of Zn2+, manganese ion-doped ferrite nanoparticles with high magnetization intensity and low Curie temperature were prepared, which solved the problem of large doses of nanoparticles and damage to normal cells in traditional magnetic induction thermal therapy, and achieved the Highly efficient and low toxic tumor treatment.
Patent Information
- Application Number
- CN202310278002.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-21
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-03-21
AI Technical Summary
Traditional magnetic induction thermal therapy methods are difficult to accurately target tumor tissue when treating tumors, and conventional magnetic nanoparticles have challenges in low Curie temperature and high heating efficiency, resulting in large doses and damage to normal cells.
By doping Mn2+ ions instead of Zn2+, MnxZn1-xAl0.4Fe1.6O4 manganese ion doped ferrite nanoparticles were prepared, which increased their saturation magnetization and low Curie temperature, achieved high heating efficiency, and was suitable for magnetic induction thermal therapy.
It realizes efficient heating of tumors at smaller doses, reduces damage to normal cells, has excellent biocompatibility and high magnetic induction performance, and meets the needs of clinical magnetic induction thermal therapy.
Smart Images

Figure CN116239155B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to a manganese ion-doped ferrite nanoparticle, a preparation method and application thereof. Background Art
[0002] Cancer, also known as malignant tumor, is a disease in which abnormal cells grow uncontrollably. Malignant cells grow and spread uncontrollably, thereby infiltrating and destroying surrounding normal tissues. Cancer has become a major public health problem worldwide. There are three main traditional treatments for malignant tumors in clinical practice, including chemotherapy, radiotherapy and surgery. Among them, surgical treatment is not suitable for tumors in sensitive parts of the human body (such as the brain) and advanced patients. In addition, although traditional radiotherapy and chemotherapy can effectively kill tumor cells, they cannot accurately target tumor tissues and have obvious toxic side effects. In view of the poor heat resistance of tumor cells compared with normal cells, in addition to the above conventional therapies, magnetic induction hyperthermia has become a novel, effective, green and safe method for treating tumors. After applying an alternating magnetic field, the implanted magnetic medium converts electromagnetic energy into thermal energy through eddy currents, hysteresis and relaxation losses, and performs precise hyperthermia on local tumors to heat the inside of the tumor to 42-46°C, thereby killing tumor cells, but causing very little damage to nearby normal tissues and cells. Among various magnetic media, spinel-structured ferrite magnetic nanoparticles (MNPs) have the most promising and widespread applications due to their excellent magnetic properties and high chemical stability. In order to minimize the potential toxicity and overheating during magnetic induction hyperthermia (MIH), the dose of MNPs used for MIH should be as small as possible and the treatment temperature should be maintained at 42-46°C throughout the treatment. Such self-regulating temperature MIH requires spinel ferrite nanoparticles with low Curie temperature and high heating efficiency (SLP) as well as good biocompatibility, which remains challenging for conventional magnetic nanoparticles. Summary of the invention
[0003] In order to solve the above technical problems, the present invention proposes a manganese ion-doped ferrite nanoparticle, a preparation method and an application thereof. 2+ Partial replacement of Zn 2+ The saturation magnetization intensity of zinc-aluminum ferrite can be effectively improved, and the goals of low Curie temperature and high heating efficiency of zinc-aluminum ferrite magnetic nanoparticles can also be achieved.
[0004] To achieve the above object, the present invention provides a manganese ion-doped ferrite nanoparticle, which is composed of: Mn x Zn 1-x Al 0.4 Fe 1.6 O4, where 0.4≤x≤0.8.
[0005] The spinel ferrite structure (XFe2O4, X = Fe, Zn, Mn, Co, etc.) is a cubic crystal system, AB2O4 type face-centered cubic structure, and its space group is O7h (F3dm). There are 56 ions in each unit cell, including 24 metal cations (16 Fe 3+ , 8 X 2+ ) and 32 oxygen ions. Doping with different cations can change the Curie temperature, magnetic properties and thermal efficiency of MNPs by changing the superexchange interaction between the tetrahedral interstitial A-site and the octahedral interstitial B-site metal ions, but this effect is unexpected. Aluminum ion is a non-magnetic metal ion that tends to occupy the B-site in the spinel ferrite structure, which can make the doped MNPs smaller, more uniform, have better magnetic properties, and reduce the Curie temperature. With the increase of Al 3+ With the increase of Ni content 0.75 Zn 0.25 Fe 2-x Al x The Curie temperature of O4 (0≤x≤1.0) dropped from 444.8℃ to 175.9℃, and CoFe 2-x Al x The Curie temperature of O4 (x = 0.0 to 0.9) drops from 529°C to 169°C, and CuFe 2-x Al l-x The Curie temperature of O4 (x≤1.6) drops from about 452°C to 152°C. However, the decrease in Curie temperature is still not enough to meet the target temperature of medium temperature (42-46°C) or high temperature (46-70°C). Each cation at the A site has 12 cations at the B site coupled to it, while each cation at the B site has only 6 cations coupled to it, so the cation occupying the A site has a greater impact on the Curie temperature of the nanoparticle. Due to the non-magnetic Zn 2+ The ion has a strong tendency to occupy the A site, so when Zn 2+ When the ion content reaches a certain concentration, the AB superexchange interaction will continue to weaken while the BB superexchange interaction will increase relatively, which will cause the spin direction of the B-site magnetic moment to randomly tilt relative to the spin direction of the A-site magnetic moment, resulting in a decrease in the specific saturation magnetization, thereby reducing the specific loss power (SLP) of the doped MNPs.
[0006] Based on this, the present invention proposes a manganese ion-doped ferrite nanoparticle (MNPs), which has high magnetic induction, saturation magnetization and excellent biocompatibility. 2+ Partial replacement of Zn 2+ The saturation magnetization intensity of MNPs can be effectively improved, and the low Curie temperature and high heating efficiency of MNPs can be achieved at the same time. 2+ Ion substitution Mnx Zn 1-x Al 0.4 Fe 1.6 Zn in O4(0.4≤x≤0.8)MNPs 2+ ions, and study their effects on magnetic properties, Curie temperature and self-controlled thermal therapy, so as to provide new MNPs to meet the needs of clinical MIH.
[0007] The matrix of the manganese ion doped ferrite nanoparticles of the present invention is zinc-aluminum ferrite, that is, a certain amount of Al is first doped with ferroferric oxide. This is because aluminum is first a non-magnetic light metal. At the same time, after doping, the grain size can be further refined, making the size distribution width narrower, which is beneficial to lowering the Curie temperature while increasing the heat production rate. This is beneficial to reducing the dosage of the nanoparticles used in clinical magnetic induction heating tumor magnetic hyperthermia therapy and can also achieve the effect of killing tumor tissue. Zinc ion doping is a common strategy because in the spinel ferrite structure, each cation at the A position is coupled with 12 cations at the B position, while each cation at the B position is only coupled with 6 cations, so the cation occupying the A position has a greater impact on the Curie temperature of the nanoparticles. Since the non-magnetic Zn 2+ The ion has a strong tendency to occupy the A site, so when Zn 2+ When the ion content reaches a certain concentration, the AB superexchange interaction will continue to weaken while the BB superexchange interaction will increase relatively, which will cause the spin direction of the B-site magnetic moment to randomly tilt relative to the spin direction of the A-site magnetic moment, resulting in a decrease in the specific saturation magnetization, thereby reducing the specific loss power (SLP) of the doped MNPs.
[0008] Therefore, it is also necessary to replace zinc ion doping zinc aluminum ferrite by manganese ion doping. The advantages of manganese ions are more obvious. On the one hand, manganese ion doped ferrite can greatly improve the initial magnetic permeability and saturation flux density of nanoparticles. In addition, the ionic radius of manganese ions is 0.067nm, the radius of divalent iron ions is 0.061nm, the radius of trivalent iron ions is 0.055nm, and the ionic radius of zinc ions is 0.074nm. It is well known that the doped ion radius is larger than that of iron and is very easy to cause lattice distortion in the process of crystal synthesis and growth, thereby reducing the crystallinity (crystallization rate). However, the ionic radius of manganese ions is very close to the Fe ions in the spinel ferrite structure, so the lattice distortion in the doping process can be effectively avoided, thereby improving the crystallization rate, which can be seen from the XRD data. When the amount of manganese ions replacing zinc ions increases, the XRD wind is sharper and the peak height is greatly increased, which is precisely because of the increased crystallization rate after manganese ion doping. On the other hand, manganese ion doped ferrite MNPs have high biocompatibility and reduce cytotoxicity.
[0009] A method for preparing the manganese ion-doped ferrite nanoparticles is synthesized by a hydrothermal method and comprises the following steps:
[0010] The iron source, aluminum source, manganese source and zinc source are dissolved in water to obtain a metal salt ion solution, which is stirred until the metal salt ion solution is clarified, and an alkali solution is added and stirred evenly to obtain a precursor solution, and a hydrothermal reaction is carried out. After the hydrothermal reaction is completed, the solution is washed, dried and ground to obtain manganese ion-doped ferrite nanoparticles.
[0011] Furthermore, in the preparation method, the molar ratio of the iron source, the aluminum source to the sum of the manganese source and the zinc source is 26.4:6.6:16.5; the molar ratio of the manganese source to the zinc source is (0.4-0.8):(0.2-0.6), and the preferred molar ratios of the manganese source to the zinc source are 0.8:0.2, 0.7:0.3, 0.6:0.4, 0.5:0.5 and 0.4:0.6.
[0012] Furthermore, in the preparation method, the iron source is FeCl3·6H2O, the aluminum source is AlCl3·6H2O, the manganese source is MnCl2·4H2O, and the zinc source is ZnCl2.
[0013] Furthermore, in the preparation method, the alkali solution is a NaOH solution with a concentration of 1 mol·L -1 .
[0014] Furthermore, in the preparation method, the hydrothermal reaction is carried out while stirring, and the stirring rate is 250 rad·min -1 .
[0015] Furthermore, in the preparation method, the temperature of the hydrothermal reaction is 300°C, the time of the hydrothermal reaction is 6 hours, and the heating rate is 2.5°C·min -1 .
[0016] Furthermore, in the preparation method, the washing is to rinse repeatedly with deionized water and anhydrous ethanol several times until neutral; and the drying is to dry in vacuum at 60° C. for 8 hours.
[0017] Furthermore, the preparation method of the manganese ion-doped ferrite nanoparticles is as follows:
[0018] Step 1: Prepare the precipitant: Dissolve 6 g of NaOH in deionized water and stir with a glass rod until it is completely dissolved. Prepare 150 mL of 1 mol·L -1 An alkaline solution is used as a precipitant;
[0019] The second step is to prepare a metal salt ion solution: ZnCl2 (purity ≥ 98%), AlCl3·6H2O (purity ≥ 99%), MnCl2·4H2O (purity ≥ 99%) and FeCl3·6H2O (purity ≥ 99%) are completely dissolved in 80 mL of deionized water according to a pre-set molar ratio to form a metal salt ion solution, wherein the predetermined molar ratio is 26.4 mmol FeCl3·6H2O, 6.6 mmol AlCl3·6H2O and a mixture of a total of 16.5 mmol MnCl2·4H2O and ZnCl2, and the molar ratios of MnCl2·4H2O and ZnCl2 in the mixture of MnCl2·4H2O and ZnCl2 are 0.8:0.2, 0.7:0.3, 0.6:0.4, 0.5:0.5 and 0.4:0.6, respectively;
[0020] The third step is to add a precipitant dropwise to generate a precursor solution: at room temperature, the precipitant prepared in the first step is added dropwise to the metal salt ion solution prepared in the previous step through a burette to perform a preliminary coprecipitation reaction to generate a precursor solution. It should be noted that the mixed solution needs to be continuously stirred during the process of adding the precipitant to ensure that the solution is evenly mixed;
[0021] Step 4: Hydrothermal reaction to generate magnetic nanoparticle suspension: Move the precursor solution prepared in step 3 to a high-temperature autoclave and seal it. Set the speed and hydrothermal reaction maintenance temperature and start heating. When the temperature in the autoclave reaches the set reaction temperature, maintain it at the reaction temperature for a certain period of time. Then let the autoclave cool naturally to room temperature, then open the autoclave and take out the formed magnetic nanoparticle suspension. The preferred speed is set to 250 rad·min -1 , the temperature of the hydrothermal reaction is 300°C, and the time of the hydrothermal reaction is 6h;
[0022] Step 5, post-treatment of magnetic nanoparticle suspension: The magnetic nanoparticle suspension obtained in step 4 is repeatedly rinsed with deionized water and anhydrous ethanol several times until the solution becomes neutral. In order to wash away the poorly crystalline MNPs in the magnetic nanoparticle suspension, the magnetic nanoparticle suspension is dispersed by water bath ultrasound for 3 minutes before washing, and the beaker containing the suspension is placed on a strong neodymium magnet so that the magnetic particles in the suspension can be quickly precipitated. After standing on the strong neodymium magnet for 2-30 minutes, the upper magnetic nanoparticle suspension is poured off under the action of the strong neodymium magnet, and then deionized water and anhydrous ethanol are added again and ultrasonicated for 3 minutes. This cycle is repeated several times until the magnetic nanoparticle suspension placed on the strong neodymium magnet can be quickly and completely precipitated within 1-2 minutes, and the upper solution becomes completely clear. After completion, the obtained precipitate is vacuum dried at 60°C for 8 hours, and then naturally cooled to room temperature. The obtained black magnetic flaky solid is fully ground to obtain magnetic nanoparticles, namely, manganese ion-doped zinc-aluminum ferrite nanoparticles.
[0023] The application of the manganese ion-doped ferrite nanoparticles in the preparation of anti-tumor drugs.
[0024] The invention discloses an application of the manganese ion-doped ferrite nanoparticles in magnetic induction hyperthermia (MIH).
[0025] Compared with the prior art, the present invention has the following advantages and technical effects:
[0026] The manganese ion-doped ferrite MNPs of the present invention have high magnetic induction, saturation magnetization and excellent biocompatibility. 2+ Partial replacement of Zn 2+ The saturation magnetization of MNPs can be effectively improved, while achieving the goals of low Curie temperature and high heating efficiency of MNPs. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] The drawings constituting a part of the present application are used to provide a further understanding of the present application. The illustrative embodiments and descriptions of the present application are used to explain the present application and do not constitute an improper limitation on the present application. In the drawings:
[0028] Figure 1 Mn x Zn 1-x Al 0.4 Fe 1.6 TEM micrographs, HRTEM images, electron diffraction images, size distribution images, XRD patterns, and particle size distribution with MnO4 (x = 0.4, 0.5, 0.6, 0.7, and 0.8) MNPs. 2+ The results of the content changes are as follows Figure 1 As shown, Mn 0.4 Zn0.6 Al 0.4 Fe 1.6 O4: (a), (b), (c), (d); Mn 0.5 Zn 0.5 Al 0.4 Fe 1.6 O4: (e), (f), (g), (h); Mn 0.6 Zn 0.4 Al 0.4 Fe 1.6 O4: (i), (j), (k), (l); Mn 0.7 Zn 0.3 Al 0.4 Fe 1.6 O4: (m), (n), (o), (p); Mn 0.8 Zn 0.2 Al 0.4 Fe 1.6 O4: (q), (r), (s), (t); where (a), (e), (i), (m) and (q) are TEM micrographs; (b), (f), (j), (n) and (r) are HRTEM images; (c), (g), (k), (o) and (s) are electron diffraction images; (c), (h), (l), (p) and (t) are size distribution images of nanoparticles (each image is from the particle size statistics of 150 nanoparticles); (u) Mn x Zn 1-x Al 0.4 Fe 1.6 XRD diffraction patterns of O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8); (v) The average size of nanoparticles increases with the increase of Mn 2 + The results of the changes in content;
[0029] Figure 2 Mn at room temperature x Zn 1-x Al 0.4 Fe 1.6 The magnetization curves and specific saturation magnetization of O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8) MNPs with the change of Mn 2+ The changes in the content of (a) nanoparticles Mn x Zn 1-x Al 0.4 Fe 1.6 Magnetization curves of O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8) at room temperature with an applied magnetic field of ±18 kOe; (b) Specific saturation magnetization with increasing doping with Mn 2+ Changes in content;
[0030] Figure 3 Mn x Zn 1-x Al 0.4 Fe 1.6 Thermogravimetric curves of O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8) MNPs under static magnetic field and Mn 2+ The influence of the change of Mn content on the Curie temperature, where (a)-(e) are the thermogravimetric curves under a static magnetic field, (f) 2+ The effect of changes in content on Curie temperature;
[0031] Figure 4 Mn x Zn 1-x Al 0.4 Fe 1.6 O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8) MNPs nanoparticle suspensions were subjected to a 32 kA·m -1 , magnetothermal temperature rise curve under alternating magnetic field with frequency of 100kHz and SLP with Mn 2+ Changes in content, where (a) 32kA·m -1 , magnetothermal temperature rise curve under an alternating magnetic field with a frequency of 100 kHz (the shaded area is the target temperature of clinical MIH: 42-46°C); (b) SLP changes with Mn 2+ Changes in content;
[0032] Figure 5 After co-culture of different cells for 24 hours, 48 hours and 72 hours, Mn 0.5 Zn 0.5 Al 0.4 Fe 1.6 O4 MNPs and 12.5-200 μg mL -1 Cytotoxicity (n=5, mean±SD, (a), (b), (c)) was significantly higher than that of the control group (n=5, mean±SD, (a), (b), (c)), with a concentration of 12.5-200 μg·mL -1 Mn 0.5 Zn 0.5 Al 0.4 Fe 1.6 Fluorescence confocal microscopy images of live and dead cells after co-culture with O4 MNPs for 72 h ((d), (e), (f)). (a) and (d) HEK-293T cell line; (b) and (e) C2C12 cell line; (c) and (f) NIH-3T3 cell line. DETAILED DESCRIPTION
[0033] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0034] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0035] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0036] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0037] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0038] The room temperature in the present invention refers to 25±2°C.
[0039] The raw materials of the present invention are all purchased and are of analytical grade.
[0040] Example 1
[0041] Mn was synthesized by hydrothermal method. 0.8 Zn 0.2 Al 0.4 Fe 1.6 O4 nanoparticles (Mn 0.8 Zn 0.2 Al 0.4 Fe 1.6 O4 MNPs), specifically:
[0042] Step 1: Prepare the precipitant: Dissolve 6 g of NaOH in deionized water and stir with a glass rod to dissolve it completely. Prepare 150 mL of 1 mol·L -1 An alkaline solution is used as a precipitant;
[0043] The second step is to prepare a metal salt ion solution: 26.4 mmol FeCl3·6H2O (purity ≥99%), 6.6 mmol AlCl3·6H2O (purity ≥99%) and a mixture of 16.5 mmol MnCl2·4H2O (purity ≥99%) and ZnCl2 (purity ≥98%) are dissolved in 80 mL of deionized water, the molar ratio of MnCl2·4H2O and ZnCl2 in the mixture of MnCl2·4H2O and ZnCl2 is 0.8:0.2, and a metal salt ion solution is obtained, which is stirred by a magnetic stirrer until the solution is completely clarified.
[0044] The third step is to add a precipitant dropwise to generate a precursor solution: at room temperature, add the precipitant prepared in the first step dropwise to the metal salt ion solution prepared in the second step through a burette, and stir for 30 minutes to perform a preliminary coprecipitation reaction to generate a precursor solution. During the process of adding the precipitant dropwise, the mixed solution needs to be continuously stirred to ensure that the solution is evenly mixed;
[0045] Step 4: Hydrothermal reaction to generate magnetic nanoparticle suspension: The precursor solution prepared in step 3 was transferred to an autoclave and sealed, and the speed was set to 250 rad·min -1 After setting the hydrothermal reaction temperature to 300 °C, the temperature was raised at a heating rate of 2.5 °C min -1 After the temperature in the autoclave rises to the set heating temperature (300°C), it is maintained at this temperature for 6 hours, then naturally cooled to room temperature, and then the autoclave is opened to take out the formed magnetic nanoparticle suspension;
[0046] Step 5, post-treatment of magnetic nanoparticle suspension: The magnetic nanoparticle suspension obtained in step 4 is repeatedly rinsed with deionized water and anhydrous ethanol several times until it is neutral. In order to wash away the poorly crystalline particles in the magnetic nanoparticle suspension, the magnetic nanoparticle suspension is dispersed by water bath ultrasound for 3 minutes before washing, and the beaker containing the suspension is placed on a strong neodymium magnet so that the magnetic particles in the suspension can be quickly precipitated. After standing on the strong neodymium magnet for 10 minutes, the upper magnetic nanoparticle suspension is poured off under the action of the strong neodymium magnet, and then deionized water and anhydrous ethanol are added and ultrasonicated again for 3 minutes. This cycle is repeated several times until the magnetic nanoparticle suspension standing on the strong neodymium magnet can be quickly and completely precipitated within 2 minutes, and the upper solution is completely clarified. After completion, the obtained precipitate is vacuum dried at 60°C in a vacuum drying oven for 8 hours, and then naturally cooled to room temperature. The obtained black magnetic flaky solid is fully ground with an agate mortar to obtain magnetic nanoparticles, namely, manganese ion-doped ferrite nanoparticles.
[0047] Example 2
[0048] Same as Example 1, except that in the second step, the molar ratio of MnCl2·4H2O to ZnCl2 in the mixture of MnCl2·4H2O and ZnCl2 is 0.7:0.3, and Mn is synthesized by hydrothermal method. 0.7 Zn 0.3 Al 0.4 Fe 1.6 O4 nanoparticles (Mn 0.7 Zn 0.3 Al 0.4 Fe 1.6 O4 MNPs).
[0049] Example 3
[0050] Same as Example 1, except that in the second step, the molar ratio of MnCl2·4H2O to ZnCl2 in the mixture of MnCl2·4H2O and ZnCl2 is 0.6:0.4, and Mn is synthesized by hydrothermal method. 0.6 Zn 0.4 Al 0.4 Fe 1.6 O4 nanoparticles (Mn 0.6 Zn 0.4 Al 0.4 Fe 1.6 O4 MNPs).
[0051] Example 4
[0052] Same as Example 1, except that in the second step, the molar ratio of MnCl2·4H2O to ZnCl2 in the mixture of MnCl2·4H2O and ZnCl2 is 0.5:0.5, and Mn is synthesized by hydrothermal method. 0.5 Zn 0.5 Al 0.4 Fe 1.6 O4 nanoparticles (Mn 0.5 Zn 0.5 Al 0.4 Fe 1.6 O4 MNPs).
[0053] Example 5
[0054] Same as Example 1, except that in the second step, the molar ratio of MnCl2·4H2O to ZnCl2 in the mixture of MnCl2·4H2O and ZnCl2 is 0.4:0.6, and Mn is synthesized by hydrothermal method. 0.4 Zn 0.6 Al 0.4 Fe 1.6 O4 nanoparticles (Mn 0.4 Zn 0.6 Al 0.4Fe 1.6 O4 MNPs).
[0055] The morphology, size distribution and crystal structure of the manganese ion-doped ferrite nanoparticles of each embodiment were obtained by transmission electron microscopy (TEM, FEI Tecnai G2 F30, USA). X-ray crystal diffractometer (XRD, PANalyticalEmpyrean X-ray diffractometer, radiation, The crystal structure was determined by a vibrating sample magnetometer (VSM, LakeShore 7400s, USA) at room temperature in a magnetic field of ±18 kOe. The mass-temperature curve was obtained using a thermogravimetric analyzer (TGA, Mettler Toledo TGA / SDTA851e, Switzerland), which can determine the Curie temperature (Tc) of the MNPs. The suspension of the manganese ion-doped ferrite nanoparticles of each example was placed in a centrifuge tube wrapped with an insulating foam layer, and the temperature was recorded in a medically safe alternating magnetic field (f = 100 kHZ, H = 32 kA m) by an optical fiber thermometer (Optocon Fotemp-Trafo FTT-0100, Germany). -1 ) concentration is 20 mg mL -1 Temperature-time curve of MNPs suspension.
[0056] Mn x Zn 1-x Al 0.4 Fe 1.6 TEM micrographs, HRTEM images, electron diffraction images, size distribution images, XRD patterns, and particle size distribution with MnO4 (x = 0.4, 0.5, 0.6, 0.7, and 0.8) MNPs. 2+ The results of the content changes are as follows Figure 1 As shown, Mn 0.4 Zn 0.6 Al 0.4 Fe 1.6 O4: (a), (b), (c), (d); Mn 0.5 Zn 0.5 Al 0.4 Fe 1.6 O 4: (e), (f), (g), (h); Mn 0.6 Zn 0.4 Al 0.4 Fe 1.6 O 4: (i), (j), (k), (l); Mn 0.7 Zn 0.3 Al0.4 Fe 1.6 O 4: (m), (n), (o), (p); Mn 0.8 Zn 0.2 Al 0.4 Fe 1.6 O 4: (a), (e), (i), (m) and (q) are TEM micrographs; (b), (f), (j), (n) and (r) are HRTEM images; (c), (g), (k), (o) and (s) are electron diffraction images; (c), (h), (l), (p) and (t) are size distribution images of nanoparticles (each image is from the particle size statistics of 150 nanoparticles); (u) Mn x Zn 1-x Al 0.4 Fe 1.6 XRD diffraction patterns of O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8); (v) The size of nanoparticles increases with the doping of Mn 2+ The results of the changes in content.
[0057] like Figure 1 As shown, it is obvious that Mn x Zn 1-x Al 0.4 Fe 1.6 O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8) presents a regular nanocubic morphology, and the size distribution obeys the log-normal distribution:
[0058]
[0059] In formula (1), D represents the size of MNPs, σ is the standard deviation of ln(D), Indicates the average particle size. Mn x Zn 1- x Al 0.4 Fe 1.6 The average sizes of O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8) are 17.3, 19.3, 23.0, 28.3 and 32.0 nm, respectively. 2+ The content increased linearly ( Figure 1 (v)). This is because during the hydrothermal reaction, Mn 2+ and Zn 2+ The total amount of Mn is fixed (16.5 mmol), and the Mn 2+ The increase in Zn content will lead to 2+The content decreases accordingly, so the content of Zn(OH)2 in the precursor solution decreases and the content of Mn(OH)2 increases. Since the saturation of Mn(OH)2 in the aqueous solution is significantly higher than that in Zn(OH)2, the increase of Mn(OH)2 and the decrease of Zn(OH)2 in the precursor will lead to an increase in ion concentration, resulting in an increase in the concentration of ions and ion cross-linked polymers that are truly dissolved in water and participate in the nucleation and growth of nanoparticles. This increase in the concentration of ions and ion cross-linked polymers accelerates the bulk diffusion and surface diffusion during the growth of nanoparticles, thereby obtaining larger nanoparticles. In the case of Mn x Zn 1-x Al 0.4 Fe 1.6 In the high-resolution TEM images of O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8), it is obvious that the interplanar spacings are 0.502, 0.266, 0.504, 0.504 and 0.504 nm, respectively, corresponding to the (111), (220), (111) and (111) planes in the spinel structure. This indicates that the synthesized Mn x Zn 1-x Al 0.4 Fe 1.6 O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8) has a spinel structure. In addition, Figure 1 (c), (g), (k), (o), and (s) show Mn x Zn 1-x Al 0.4 Fe 1.6 The presence of diffraction rings corresponding to the characteristic crystal planes of spinel (220), (311), (400), (511) and (440) also confirms that Mn x Zn 1-x Al 0.4 Fe 1.6 Spinel structures of O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8) MNPs.
[0060] Figure 1 The middle (u) shows Mn x Zn 1-x Al 0.4 Fe 1.6 XRD diffraction patterns of O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8). It is worth noting that the diffraction peaks of all samples are sharp and narrow, indicating that these MNPs have good crystallinity. 2+The diffraction peaks of the prepared magnetic nanoparticles increased significantly with the increase in the amount of zinc ions with larger ionic radius, indicating that the crystallinity was greatly improved after doping with divalent and trivalent iron ions close to the ferrite itself. The phase search results showed that the diffraction peaks of all samples were consistent with the PDF card (JCPSDS-ICDD database number 85-1202, Mn 0.6 Fe 2.07 Zn 0.29 O4) on the spinel structure (220), (311), (222), (400), (422), (511) and (440) match the characteristic peaks, and no other obvious impurity phases appear, indicating that Mn x Zn 1-x Al 0.4 Fe 1.6 O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8) is a single-phase cubic spinel structure. According to the Scherrer formula, Mn x Zn 1-x Al 0.4 Fe 1.6 The average grain sizes of O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8) are 15.5, 19.3, 20.2, 26.0 and 29.7 nm, respectively, which is consistent with the statistical trend obtained by TEM.
[0061] Mn at room temperature x Zn 1-x Al 0.4 Fe 1.6 The magnetization curves of O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8) are more similar to the saturation magnetization curves of Mn 2+ The changes in content can be seen Figure 2 . Figure 2 (b) shows the specific saturation magnetization (σs) of the nanoparticles in each example relative to Mn 2+ Obviously, with the change of Mn 2+ As the content x increases from 0.4 to 0.8, σs increases linearly from 30.2 to 54.2 emu·g -1 .
[0062] In spinel ferrite, the specific saturation magnetization is proportional to the molecular formula unit ( nB ) is proportional to the total magnetic moment as follows:
[0063]
[0064] In formula (2), M s is the specific saturation magnetization, M W is the molecular weight of MNPs. BIt depends on the superexchange interaction between the metal ions at the A and B sites. There are three types of superexchange interactions, namely AA, BB and AB, among which AB superexchange interaction is the strongest, followed by BB superexchange interaction, and AA superexchange interaction is the weakest. However, when there is an excess of non-magnetic Zn at the A site in spinel ferrite 2+ When n is , the magnetic moment of the A site is smaller, and the magnetic moment of the B site tends to be closer to the magnetic moment of the A site, making the BB superexchange interaction stronger than the AB superexchange interaction. B It is described by the Yafet Kittle (YK) model and is expressed as:
[0065] n B =M B cosα Y-K -M A (3)
[0066] In formula (3), α Y-K is the YK angle, which reflects the effect of nonmagnetic ions on the AB superexchange interaction. x Zn 1-x Al 0.4 Fe 1.6 Zn in O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8) 2+ When the content is greater than 0.2, it will result in a larger YK angle and a smaller M s . Since in spinel ferrite, Mn 2+ Zn 2+ Prefers to occupy the A site, and the doped magnetic moment is greater than that of Zn 2+ Mn 2 + This may lead to an increase in the A-site magnetic moment and an enhancement in the AB superexchange interaction, which in turn leads to a decrease in the YK angle. x Zn 1- x Al 0.4 Fe 1.6 The specific saturation magnetization of O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8) MNPs generally increases with the increase of Mn 2+ Increases with the increase of content.
[0067] Mn x Zn 1-x Al 0.4 Fe 1.6 Thermogravimetric curves of O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8) MNPs under static magnetic field and Mn 2+ The effect of the change in content on the Curie temperature is as follows Figure 3It is noteworthy that the normalized mass of MNPs gradually increases with temperature until it reaches a plateau, reflecting the decrease in the specific saturation magnetization of MNPs. Figure 3 The insets of (a)-(e) show the first derivative of the corresponding thermogravimetric curves. The peak value represents the temperature at which the magnetization intensity of most MNPs becomes zero, which is defined as the Curie temperature (T C ). The data of the present invention show that Mn x Zn 1-x Al 0.4 Fe 1.6 The Curie temperatures of O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8) MNPs are 47.5, 54.4, 76.8, 118.5 and 257.8 °C, respectively.
[0068] like Figure 3 As shown in (f), Mn x Zn 1-x Al 0.4 Fe 1.6 The Curie temperature of O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8) MNPs increases with the Mn 2+ content. The Curie temperature is the phase transition temperature of a magnetic material from a ferromagnetic phase to a paramagnetic phase. The Curie temperature of MNPs is determined by the superexchange interaction between metal ions. The stronger the interaction, the higher the Curie temperature. Therefore, the Curie temperature of spinel ferrite is a function of the superexchange interaction between metal ions at the A and B sites. The superexchange interaction can be enhanced by increasing the magnetic moments of the A and B sites or reducing the distance between the magnetic ions at the A and B sites, thereby increasing the Curie temperature of spinel ferrite. Spinel ferrite has a face-centered cubic structure, and the cations at the A site are coupled to 12 cations at the B site, while the cations at the B site are only coupled to 6 cations at the A site. Therefore, the influence of the cations at the A site on the AB superexchange interaction is greater than that at the B site. Due to Mn 2+ The magnetic moment (Mn 2+ =5μB) greater than Zn 2+ , Mn 2+ Replace Zn 2+ The superexchange interaction of the AB sites can be enhanced by increasing the magnetic moment of the A site, resulting in a decrease in the Curie temperature with the increase of Mn 2+ increases with the increase of doping ratio.
[0069] Figure 4 (a) shows Mn x Zn 1-x Al 0.4 Fe 1.6 O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8) MNPs aqueous suspension at 20 mg mL -1The magnetothermal temperature rise curve under the condition of 100kHz alternating magnetic field strength of 32kA·m -1 , satisfying H×f<5×10 9 Am -1 ·s -1 The temperature of the suspension increased rapidly after the alternating magnetic field was applied, indicating that the MNPs generated a lot of heat. It is worth noting that after 10 minutes of magnetic heating, the Mn 0.6 Zn 0.4 Al 0.4 Fe 1.6 O4、Mn 0.5 Zn 0.5 Al 0.4 Fe 1.6 O4 and Mn 0.4 Zn 0.6 Al 0.4 Fe 1.6 The temperature change in the suspension of O4 becomes less significant. This is because the increase in temperature destroys the magnetic ordered structure of MNPs, resulting in a decrease in their magnetization and thus a decrease in heat generation capacity. When the temperature approaches the Curie temperature, the ordered state of the magnetic moment of most MNPs disappears, resulting in the disappearance of the magnetization and heat generation capacity of the MNPs. In addition, after heating for 3 and 5 minutes, the Mn 0.8 Zn 0.2 Al 0.4 Fe 1.6 O4 and Mn 0.7 Zn 0.3 Al 0.4 Fe 1.6 The temperature of the O4 suspension has reached 76°C. Since this temperature exceeds the upper limit of the hyperthermia temperature requirement and lacks clinical significance, the measurement is stopped.
[0070] After heating for 30 minutes, Mn 0.6 Zn 0.4 Al 0.4 Fe 1.6 O4、Mn 0.5 Zn 0.5 Al 0.4 Fe 1.6 O4 and Mn 0.4 Zn 0.6 Al 0.4 Fe 1.6 The temperatures of the O4 suspensions were stabilized at 59.4°C, 45.4°C, and 41.6°C, respectively, which are lower than the Curie temperatures of the particles themselves (76.8°C, 54.4°C, and 47.5°C, respectively). This difference is mainly due to the influence of heat exchange between the MNPs suspension and the environment.
[0071] In order to quantitatively study the thermal efficiency, the specific power loss of the nanoparticles under the alternating magnetic field was calculated:
[0072]
[0073] In formula (4), C is the specific heat capacity of MNPS suspension; m s and m p are the masses of MNPs suspension and MNPs, respectively; dT / dT| t→0 is the initial slope of the magnetothermal temperature rise curve. Figure 4 The data shown in (a) are Mn x Zn 1-x Al 0.4 Fe 1.6 The SLPs of O4 (x = 0.4, 0.5, 0.6, 0.7 and 0.8) MNPs were 6.3, 11.1, 17.2, 39.7 and 54.5 W·g, respectively. -1 .from Figure 4 As can be seen in (b), as Mn 2+ With the increase of Mn content, the SLP of nanoparticles gradually increases. The SLP value of nanoparticles is positively correlated with the specific saturation magnetization. When x≤0.6, Mn x Zn 1-x Al 0.4 Fe 1.6 The SLP value of O4 varies with Mn 2+ content increases linearly, which can be attributed to the linear increase in the specific saturation magnetization of MNPs. 2+ When the content is greater than 0.6, the SLP value deviates from the above linear relationship, which may be due to the size effect, in which the size of MNPs will change the SLP value by affecting its total relaxation time, and when the total relaxation time of MNPs matches the field frequency well, it will reach the maximum SLP value.
[0074] Cell culture and cytotoxicity assay of manganese ion-doped zinc-aluminum ferrite nanoparticles
[0075] HEK-293T (human embryonic kidney cells), C2C12 (mouse myoblasts) and NIH-3T3 (mouse embryonic fibroblasts) were maintained in a cell culture medium consisting of 89% high glucose Dulbecco's modified medium (DMEM), 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (PS) and cultured in a humidified incubator (Thermos HREAcell 150i, USA). The nanoparticles MNPs of each embodiment were first disinfected with 75% (volume fraction) ethanol for 24 hours and then rinsed three times with phosphate buffered saline (PBS). MNPs were dispersed in cell culture media with concentrations of 0 μg / mL, 12.5 μg / mL, 25 μg / mL, 50 μg / mL, 100 μg / mL and 200 μg / mL, respectively.
[0076] The cell counting kit 8 (CCK-8) was used to quantitatively evaluate the cytotoxicity of magnetic nanoparticles on HEK-293T, C2C12, and NIH-3T3 cells. Specifically, cells were plated at 5 × 10 4 The cells were seeded into 96-well plates at a density of 100 μL of cell culture medium without MNPs. The cells were cultured at 37 °C and 5% carbon dioxide for 3 h, and then 100 μL of culture medium containing different concentrations of sterilized MNPs was added. After co-culture with MNPs for 24, 48, and 72 h, 10 μL of CCK-8 reagent was added to each well and incubated for 3 h, and then the supernatant was transferred to a new microplate and the absorbance of methyl benzoate in the culture medium was measured using a microplate reader (SPECTRAFLUOR, TECAN, Sunrise, Austria). The cell viability (VR) was calculated using the following formula:
[0077]
[0078] In formula (5), OD B is the absorbance of DMEM medium alone, OD C is the absorbance of DMEM medium containing cells only, while OD N is the absorbance of the DMEM-medium containing MNPs and cells.
[0079] In addition, a live / dead cell double staining kit was used to detect the cytotoxicity of MNPs at different concentrations. After 72 hours of co-culture, the cells were washed twice with PBS, stained with LiveDye and NucleiDye (1:1000 dilution, volume ratio), incubated in the dark at 37°C for 30 minutes, and washed twice with PBS solution. Fluorescence imaging of live and dead cells was then performed on a confocal microscope (Nikon A1 HD25, Japan).
[0080] MNPs for research and clinical applications usually need to be injected into biological tissues in situ. Therefore, the biocompatibility of MNPs is of great importance. Here, the present invention uses the CCK-8 method to synthesize Mn 0.5 Zn 0.5 Al 0.4 Fe 1.6 O4 particles (Mn 0.5 Zn 0.5 Al 0.4 Fe 1.6 After co-culture of HEK-293T, C2C12, and NIH-3T3 cells with O4 MNPs, the survival rates of HEK-293T, C2C12, and NIH-2T3 cells were quantitatively evaluated. Figure 5 As shown in (a)-(c), after incubation with MNPs for 24, 48, and 72 hours, the viability of HEK-293T, C2C12, and NIH-3T3 cells exceeded 88%, and there was no significant difference between the MNPs experimental and control groups. Figure 5 (e)-(f) show the growth of HEK-293T, C2C12 and NIH-3T3 cell lines in vitro with different concentrations of Mn 0.5 Zn 0.5 Al 0.4 Fe 1.6 The results of live-death staining of cells after 72 hours of co-culture with O4 MNPs also showed no significant toxicity. 0.5 Zn 0.5 Al 0.4 Fe 1.6 O4 MNPs in the range of 0-200 μg·mL -1 It has excellent biocompatibility at certain concentrations, indicating that it has strong potential for clinical application.
[0081] In summary, the present invention successfully synthesized regular nanocubic nanoparticles Mn with spinel crystal structure by hydrothermal method. x Zn 1-x Al 0.4 Fe 1.6 O4(0.4≤x≤0.8). With the increase of Mn 2+ The increase of Mn content x Zn 1-x Al 0.4 Fe 1.6 The specific saturation magnetization of O4 (0.4≤x≤0.8) increases linearly from 30.2 to 54.2 emu·g -1 In addition, as Mn 2+ The increase of Mn content x Zn 1-x Al 0.4Fe 1.6 The Curie temperature of O4 increases linearly from 47.5℃ to 257.8℃. -1 Clinically safe 100kHz alternating magnetic field, with Mn 2+ The increase of Mn content x Zn 1-x Al 0.4 Fe 1.6 The SLP of O4 increased from 6.3 to 54.5 W·g -1 It is worth noting that Mn 0.5 Zn 0.5 Al 0.4 Fe 1.6 O4 MNPs have good biocompatibility and SLP is 11.1 W·g -1 In addition, Mn 0.5 Zn 0.5 Al 0.4 Fe 1.6 O4 MNPs can achieve self-regulating and self-temperature-controlled magnetic induction heating therapy at 45.4°C, and therefore have great application potential in clinical MIH.
[0082] The above are only preferred specific implementations of the present application, but the protection scope of the present application is not limited thereto. Any changes or substitutions that can be easily thought of by a person skilled in the art within the technical scope disclosed in the present application should be included in the protection scope of the present application. Therefore, the protection scope of the present application should be based on the protection scope of the claims.
Claims
1. An application of manganese ion-doped ferrite nanoparticles in the preparation of anti-tumor drugs, characterized in that: The manganese ion-doped ferrite nanoparticles have low Curie temperature and high heating efficiency; The method for preparing the manganese ion-doped ferrite nanoparticles comprises the following steps: Step 1: Prepare the precipitant: Dissolve 6 g of NaOH in deionized water and stir with a glass rod to dissolve it completely. Prepare 150 mL of 1 mol·L -1 An alkaline solution is used as a precipitant; The second step is to prepare a metal salt ion solution: 26.4 mmol of FeCl3·6H2O with a purity of ≥99%, 6.6 mmol of AlCl3·6H2O with a purity of ≥99%, and a total of 16.5 mmol of a mixture of MnCl2·4H2O with a purity of ≥99% and ZnCl2 with a purity of ≥98% are dissolved in 80 mL of deionized water, the molar ratio of MnCl2·4H2O to ZnCl2 in the mixture of MnCl2·4H2O and ZnCl2 being 0.5:0.5, to obtain a metal salt ion solution, which is stirred by a magnetic stirrer until the solution is completely clear; The third step is to add a precipitant dropwise to generate a precursor solution: the precipitant prepared in the first step is added dropwise to the metal salt ion solution prepared in the second step through a burette at room temperature, and stirred for 30 minutes to perform a preliminary co-precipitation reaction to generate a precursor solution. During the process of adding the precipitant dropwise, the mixed solution needs to be continuously stirred to ensure uniform mixing of the solution; Step 4: Hydrothermal reaction to generate magnetic nanoparticle suspension: The precursor solution prepared in step 3 was transferred to an autoclave and sealed, and the speed was set to 250 rad·min -1 After setting the hydrothermal reaction temperature to 300 °C, the temperature was raised at a heating rate of 2.5 °C min -1 After the temperature in the autoclave rises to the set heating temperature of 300°C, it is maintained at this temperature for 6 hours, then naturally cooled to room temperature, and then the autoclave is opened to take out the formed magnetic nanoparticle suspension; Step 5, post-treatment of the magnetic nanoparticle suspension: The magnetic nanoparticle suspension obtained in the fourth step is repeatedly rinsed with deionized water and anhydrous ethanol several times until it is neutral. In order to rinse out the poorly crystalline particles in the magnetic nanoparticle suspension, the magnetic nanoparticle suspension is dispersed by water bath ultrasound for 3 minutes before washing. The beaker containing the suspension is placed on a strong neodymium magnet so that the magnetic particles in the suspension can be quickly precipitated. After standing on the strong neodymium magnet for 10 minutes, the upper layer of magnetic nanoparticles is dumped off under the action of the strong neodymium magnet. The suspension was then added with deionized water and anhydrous ethanol and ultrasonicated for 3 minutes again, and this cycle was repeated several times until the magnetic nanoparticle suspension placed on the strong neodymium magnet could be quickly and completely precipitated within 2 minutes, and the upper solution was completely clarified. After completion, the obtained precipitate was vacuum dried in a vacuum drying oven at 60°C for 8 hours, and then naturally cooled to room temperature. The obtained black magnetic flaky solid was fully ground with an agate mortar to obtain magnetic nanoparticles, namely manganese ion-doped ferrite nanoparticles, denoted as Mn 0.5 Zn 0.5 Al 0.4 Fe 1.6 O4.
Citation Information
Patent Citations
Spinel type multiferroics and synthesizing method thereof
CN102219490A
Self-assembly rod-shaped manganese-zinc ferrite magnetic material and preparation method thereof
CN103214037A
Hydrothermal synthesis preparation method of zinc doped superparamagnetic ferroferric oxide nano particle
CN105271433A
Preparing process of nano Mn-Zn ferrite material
CN1986426A
Pharmaceutical composition for preparing injection solution when used in treating magnetic hyperthermia and method for preparing thereof
RU2742196C1
